AN2 Therapeutics Inc
NASDAQ:ANTX

Watchlist Manager
AN2 Therapeutics Inc Logo
AN2 Therapeutics Inc
NASDAQ:ANTX
Watchlist
Price: 1.1 USD Market Closed
Market Cap: 30.1m USD

Relative Value

There is not enough data to reliably calculate the relative value of ANTX.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ANTX Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
2.6
vs History
vs Industry
Median 3Y
-1.1
Median 5Y
-2.4
Industry
21.7
Forward
-1
vs History
vs Industry
Median 3Y
-1.2
Median 5Y
-3
Industry
16.6
vs History
vs Industry
Median 3Y
-1.2
Median 5Y
-3
Industry
22.5
vs History
74
vs Industry
74
Median 3Y
0.7
Median 5Y
1
Industry
2.3
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
2.9
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
5.5
vs History
12
vs Industry
53
Median 3Y
0.5
Median 5Y
-0.5
Industry
13.1
vs History
12
vs Industry
51
Median 3Y
0.5
Median 5Y
-0.5
Industry
16.6
Forward
0.9
vs History
4
vs Industry
54
Median 3Y
0.6
Median 5Y
-0.7
Industry
15.8
vs History
4
vs Industry
41
Median 3Y
0.6
Median 5Y
-0.7
Industry
19.1
vs History
vs Industry
55
Median 3Y
-3.2
Median 5Y
-3.2
Industry
1.9

Multiples Across Competitors

ANTX Competitors Multiples
AN2 Therapeutics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
AN2 Therapeutics Inc
NASDAQ:ANTX
29.7m USD 0 -0.9 0.9 0.9
US
Eli Lilly and Co
NYSE:LLY
943.6B USD 15.9 51.2 34.5 36.9
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
485.1B USD 5.3 19.3 15.8 20.5
CH
Roche Holding AG
SIX:ROG
253.2B CHF 4.1 26.9 11.5 13.4
UK
AstraZeneca PLC
LSE:AZN
213.3B GBP 4.9 30.2 108.4 158.6
CH
Novartis AG
SIX:NOVN
204.9B CHF 4.5 17.6 11.2 14.5
US
Merck & Co Inc
NYSE:MRK
246.1B USD 3.8 12.9 9.2 11
DK
Novo Nordisk A/S
CSE:NOVO B
1.3T DKK 4.2 12.9 9 10.5
IE
Endo International PLC
LSE:0Y5F
202.5B USD 87.3 -69.3 321.2 805.4
US
Pfizer Inc
NYSE:PFE
146.5B USD 2.3 14.9 7.6 10.3
P/E Multiple
Earnings Growth PEG
US
AN2 Therapeutics Inc
NASDAQ:ANTX
Average P/E: 23.2
Negative Multiple: -0.9
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
51.2
53%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.3
29%
0.7
CH
Roche Holding AG
SIX:ROG
26.9
29%
0.9
UK
AstraZeneca PLC
LSE:AZN
30.2
38%
0.8
CH
Novartis AG
SIX:NOVN
17.6
17%
1
US
Merck & Co Inc
NYSE:MRK
12.9
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
12.9
4%
3.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -69.3 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.9
29%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
AN2 Therapeutics Inc
NASDAQ:ANTX
Average EV/EBITDA: 397.8
0.9
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
34.5
33%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
15.8
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.5
4%
2.9
UK
AstraZeneca PLC
LSE:AZN
108.4
10%
10.8
CH
Novartis AG
SIX:NOVN
11.2
6%
1.9
US
Merck & Co Inc
NYSE:MRK
9.2
6%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
9
2%
4.5
IE
E
Endo International PLC
LSE:0Y5F
321.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.6
1%
7.6
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
AN2 Therapeutics Inc
NASDAQ:ANTX
Average EV/EBIT: 1 707.7
0.9
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
36.9
36%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
20.5
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.4
5%
2.7
UK
AstraZeneca PLC
LSE:AZN
158.6
23%
6.9
CH
Novartis AG
SIX:NOVN
14.5
12%
1.2
US
Merck & Co Inc
NYSE:MRK
11
8%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
10.5
1%
10.5
IE
E
Endo International PLC
LSE:0Y5F
805.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
8%
1.3